CLAIMS

1. A composition comprising:

(i) a culture-expanded population of mesenchymal lineage precursor or stem cells (MLPSCs) or extracellular vesicles obtained therefrom, in which the MLPSCs have been culture expanded in media containing:

IFN-gamma and/or TNF-alpha; and/or,

one or more pro-inflammatory cytokines selected from the group consisting of IL-6; IL-8; IL-17A; MCP-1; MIP-1-alpha; MIP-1-beta; IP-10, preferably in which the extracellular vesicles are exosomes.

2. A composition according to Claim 1, in which the media contains three or more pro-inflammatory cytokines.

3. A composition according to Claim 1 or 2, in which the media contains two or more pro-inflammatory cytokines selected from the group consisting of IL-6; IL-8; IL-17A; MCP-1; MIP-1-alpha; MIP-1-beta; IP-10.

4. A composition according to Claim 1, 2 or 3, in which the level of IFN-gamma is < 1 ng/ml, preferably < 500 pg/ml, more preferably < 100 pg/ml; and/or in which the level of TNF-alpha is < 1 ng/ml, preferably < 750 pg/ml, more preferably < 400 pg/ml.

5. A composition according to any preceding claim, in which the media is characterised by one or more or all of the following:

(i) a level of IFN-gamma greater than 1 pg/ml;

(ii) a level of TNF-alpha greater than 2 pg/ml;

(iii) a level of IL-6 greater than 3 pg/ml;

(iv) a level of IL-8 greater than 500 pg/ml;

(v) a level of IL-17A greater than 0.2 pg/ml;

(vi) a level of MCP-1 greater than 3 pg/ml;

(vii) a level of MIP-1-alpha greater than 0.5 pg/ml;

(viii) a level of MIP-1-beta greater than 3 pg/ml;

(ix) a level of IP-10 greater than 500 pg/ml.

6. A composition according to any preceding claim, in which the media contains serum which comprises the pro-inflammatory cytokines.

7. A composition according to Claim 6, in which:

the serum is newborn mammalian serum;

the serum is newborn calf serum;

the serum is obtained no more than 21 days after birth;

the newborn serum is postnatal day 1 to postnatal day 7 newborn serum;

the media comprises at least 5% (v/v) newborn mammalian serum;

the serum is at a concentration of about 2% (v/v) to about 12% (v/v); or

the media comprises a foetal and a newborn serum from the same species and the ratio of the concentration of the foetal serum to the concentration of the newborn serum is 1:1 or lower, optionally in which the concentration of the foetal serum and the concentration of newborn serum are each 5% (v/v).

8. A composition according to any of Claims 1 to 5, in which the media is serum free.

9. A composition according to any preceding claim, in which the MLPSCs express an increased level of angiogenin relative to a control population and/or the MLPSCs or extracellular vesicles obtained therefrom induce increased levels of one or more of endothelial network formation, endothelial length, or endothelial branch length, relative to a control population, preferably in which the control population is a population of MLPSCs or extracellular vesicles obtained therefrom that have been culture expanded in a cell culture medium comprising 10% foetal serum.

10. A composition according to any preceding claim, in which:

the MLPSCs express a level of angiogenin greater than about 1200 pg/ml;

the MLPSCs express a level of SDF-1 greater than about 3000 pg/ml;

the MLPSCs express a level of VEGF greater than about 3200 pg/ml;

conditioned media from the MLPSCs induces endothelial network formation greater than about 0.12 mm^2/mm^2;

conditioned media from the MLPSCs induces endothelial network length greater than about 5 mm^2/mm^2; and/or

conditioned media from the MLPSCs induces endothelial branch length greater than about 15 $1/mm^2$.

11. A cryopreserved composition comprising:

(i) a culture-expanded population of mesenchymal lineage precursor or stem cells (MLPSCs) or extracellular vesicles obtained therefrom, in which the MLPSCs have been culture expanded in media containing newborn mammalian serum obtained no more than 21 days after birth; and,

(ii) a cryopreservative, preferably in which the extracellular vesicles are exosomes, and optionally in which the MLPSCs are cryopreserved at least twice.

12. An *in vitro* method for pre-licensing human mesenchymal lineage precursor or stem cells (MLPSCs) or extracellular vesicles obtained therefrom, the method comprising culturing the MLPSCs in media containing:

(i) IFN-gamma and/or TNF-alpha; and/or, one or more pro-inflammatory cytokines selected from the group consisting of IL-6; IL-8; IL-17A; MCP-1; MIP-1-alpha; MIP-1-beta; IP-10; and/or,

(ii) newborn mammalian serum obtained no more than 21 days after birth,

preferably in which the extracellular vesicles are exosomes.

13. A composition produced by a method according to Claim 12.

14. A composition or method according to any preceding claim, in which:

the MLPSCs are maintained in an undifferentiated state.

the MLPSCs are human mesenchymal stem cells (hMSCs); and/or

the MLPSCs are culture-expanded from a population of STRO-1^+ multipotential cells.

15. A media for culturing MLPSCs, the media comprising:

IFN-gamma and/or TNF-alpha; and

one or more pro-inflammatory cytokines, in which the pro-inflammatory cytokines are selected from the group consisting of IL-6; IL-8; IL-17A; MCP-1; MIP-1-alpha; MIP-1-beta; IP-10.